NL-OMON22008招募中不适用
owering of very long chain fatty acids in patients with X-linked adrenoleukodystrophy (X-ALD): A biochemical study.
Trial medication was provided by Merck, Sharp and Dome (MSD)0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male patients with X-ALD (confirmed by biochemical analysis or mutation analysis of the ABCD1 gene);
- •2. 18 years or older;
- •3. Able to give informed consent and visit the hospital;
- •4. No contraindications for use of trial medication.
排除标准
- •1. Use of another cholesterol lowering drug;
- •2. Liver disease or CK more than 3 times baseline level;
- •3. Use of very long chain fatty acid lowering therapy (e.g. Lorenzo's oil) in the 8 weeks preceding the study.
研究者
相似试验
已完成
不适用
owering Of Very long chain fatty Acids in patients with X-linked adrenoleukodystrophy: a biochemical studyAdrenoleukodystrophyX-linked adrenoleukodystrophy (X-ALD)Nervous System DiseasesISRCTN31565393Academic Medical Centre (AMC) (Netherlands)20
已完成
不适用
Acute Effects of Dietary Medium-chain Fatty Acids on Lipid ProfileHealthy NutritionDiet, HealthyNCT06368271University of Copenhagen4
招募中
不适用
Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy IndividualsMedium-chain Acyl-CoA Dehydrogenase DeficiencyNCT06623032University of Copenhagen30
终止
不适用
Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring ProgramLong-chain Fatty Acid Oxidation Disorders (LC-FAOD)NCT04812106Ultragenyx Pharmaceutical Inc8
已完成
不适用
Apolipoprotein (APO)E Genotype, Meal Fatty Acids, Postprandial LipaemiaCardiovascular DiseaseNCT01522482University of Reading31